

resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? *Eur Urol*. 2016; 69(2): 231–244.

**4. Järvinen R, Kaasinen E, Sankila A, et al.** Long-term efficacy of maintenance bacillus Calmette-Guerin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up. *Eur Urol* 2009; 56: 260.

**5. Sylvester RJ, van der Meijden AP, Witjes JA, et al.** Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. *J Urol*. 2005; 174: 86.

**6. Malmström PU, Sylvester RJ, Crawford DE, et al.** An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. *Eur Urol* 2009; 56: 247.

**7. Sylvester RJ, van der Meijden AP, Lamm DL.** Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. *J Urol*. 2002 168(5): 1964–1970.

**8. Babjuk M, Burger M, Compérat E, et al.** EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2016. *Eur Urol*. 2017; 71(3): 447–461.

**9. Colombo R, Da Pozzo LF, Lev A, et al.** Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors. *J Urol*. 1998; 159: 783–787.

**10. Curley SA, Palalon F, Sanders KE, Koshkina NV.** The effects of non-invasive radiofrequency treatment and hyperthermia on malignant and nonmalignant cells. *Int J Environ Res Public Health*. 2014; 11(9): 9142–9453.

**11. Brisuda A, Babjuk M, Stolz J.** Intravezikální chemoterapie s využitím tepelné energie u pacientů s uroteliálním karcinomem močového měchýře bez invaze svaloviny – zkušenosti jednoho pracoviště. *Ces Urol* 2017; 21(2): 122–128.

**12. Colombo R, Da Pozzo LF, Salonia A, et al.** Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. *J Clin Oncol*. 2003; 21(23): 4270–4276.

**13. Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D.** Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). *BJU Int*. 2011; 107: 912–918.

**14. Arends TJ, Nativ O, Maffezzini M, et al.** Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guérin for adjuvant treatment of patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer. *Eur Urol*. 2016; 69(6): 1046–1052.

**15. Lammers RJ, Witjes JA, Inman BA, et al.** The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: a systematic review. *Eur Urol*. 2011; 60: 81–93.

**16. Halachmi S, Moskovitz B, Maffezzini M, et al.** Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder. *Urol Oncol*. 2011; 29(3): 259–264.

**17. Sousa A, Piñeiro I, Rodríguez S, et al.** Recirculant Hyperthermic IntraVesical Chemotherapy (HIVEC) in intermediate-high-risk non-muscle-invasive bladder cancer. *Int J Hyperthermia*. 2016; 32(4): 374–380.